CA-XPRIZE
9.3.2021 09:33:12 CET | Business Wire | Press release
XPRIZE , the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, in partnership with Cognizant (Nasdaq: CTSH), one of the world's leading technology and professional services companies, today announced the Grand Prize Winners in the $500K Pandemic Response Challenge . The four-month global competition was designed to harness the power of data and artificial intelligence in equipping policymakers, health officials and business leaders with the insights and guidance necessary to implement public safety measures that help keep local economies open while minimizing virus outbreaks as vaccines become more widely available. These decision-makers are encouraged to use the results, methodologies and technology from the challenge as reference on approaches to minimize potential outbreaks, now and moving forward.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005419/en/
Winning first place honors is the VALENCIA IA4COVID19 (Valencia, Spain) team, coordinated by Dr. Nuria Oliver, Commissioner of the Presidency of the Generalitat Valenciana, and J. Alberto Conejero, Director of the Applied Mathematics Department at Universitat Politècnica de València. In second place is JSI vs COVID (Ljubljana, Slovenia), coordinated by Mitja Lustrek, Head of the Ambient Intelligence Group at the Jozef Stefan Institute, whose team members were previous competitors in the Qualcomm Tricorder XPRIZE. These top-performing teams were selected from among 48 finalists in 17 countries. Both teams will share equally the total prize purse of $500,000, however judges have chosen to distinguish team VALENCIA IA4COVID19 as first place due to their exemplary submissions. In total, over 100 teams throughout the world initially joined the competition.
The Pandemic Response Challenge required teams to build effective data-driven AI systems capable of accurately predicting COVID-19 transmission rates and prescribing intervention and mitigation measures that, with testing in “what-if” scenarios, were shown to minimize infection rates as well as negative economic impacts. The winning models will be made available to policymakers, business leaders, and health officials worldwide as they consider strategies for safely reopening society and restoring the global economy.
"We are absolutely thrilled to announce the winners of the Pandemic Response Challenge, and are extremely grateful to Cognizant for their support during this competition,” said Amir Banifatemi, Chief Innovation and Growth Officer of XPRIZE. “This month marks a year since the beginning of the COVID-19 outbreak globally, and since then we have sought out various ways in which XPRIZE can help to identify and accelerate possible solutions for COVID-19 as well as strategies to keep people safe while mitigating for a back to normal world. Our hope now is to implement the methodology and technology identified via this challenge into emergency response plans for local governments worldwide, utilizing artificial intelligence to better protect everyone – from the most vulnerable in our society to the most essential workers – against future pandemics.”
“We salute the ingenuity and dedication of the two winning teams of the Pandemic Response Challenge, VALENCIA IA4COVID19 and JSI vs COVID, and thank all who participated in this global competition,” said Brian Humphries, CEO of Cognizant. “It’s amazing what can happen when you bring together creative minds in data science, computer programming, machine learning, and epidemiology. Their data-driven, AI-based models will help policy makers and health officials safely restart economies and learn how to harness these technologies to tackle future public health crises.”
Contestants’ AI models were evaluated by an independent judging panel comprising academics, pandemic response specialists, AI experts, and epidemiologists, among others. Both grand prize-winning teams succeeded in creating effective models and meeting judging criteria that included both quantitative metrics and qualitative factors such as:
- Actionability and Usability of the models in real-world settings;
- Inclusivity and Fairness, which assessed how the models take into account particularly vulnerable groups;
- Collaborative Contributions that awarded teams who created open source models or contributed data and models for the shared success of all;
- Innovation, which considered whether teams found innovative ways to extend the scope of the Challenge
Complete judging criteria and Challenge guidelines are available on the XPRIZE website.
VALENCIA IA4COVID19 has collaborated with the Valencian government since March 2020 to leverage data science in the fight against COVID-19. Ultimately, the team’s winning model successfully forecasted epidemiological evolution through their use of AI and data science. JSI vs COVID worked to develop accurate predictors of COVID-19 infections using a combination of a SEIR epidemiological model and machine learning. Through the Challenge, both teams hope to achieve more accurate models for predicting the evolution of COVID-19 that can be used in their respective countries and beyond.
In addition to the two grand prize winners, eight other teams have received honorable mentions and will each receive $3,000 in AWS credits for cloud and compute services, courtesy of AWS, a supporting partner of the Challenge. These teams are:
- metis2020 (Los Angeles, Calif., US)
- mvsm (Berlin, Germany)
- CoronaSurveys (Madrid, Spain)
- Nixtamal AI (Mexico City, Mexico)
- Shanvi (San Diego, Calif., US)
- Kangaroos (Ultimo, Australia)
- ADVANCE4COVID (Rochester, NY, US)
- Nebraska team (Omaha, Neb., US)
All teams competing in the Pandemic Response Challenge used Cognizant’s foundational research and Evolutionary AI™ modeling as a baseline, building out their models using data compiled by the Oxford COVID-19 Government response tracker (based at Oxford University’s Blavatnik School of Government). The Pandemic Response Challenge was first launched in November 2020, and comprised two phases:
- Phase 1, concluded in January 2021: Contestants analyzed local COVID-19 data, existing intervention strategies, and common mitigation policies to develop and test prediction models capable of anticipating global infection spikes.
- Phase 2, concluded in February 2021: Contestants developed a “prescriptor ” model, which could suggest realistic intervention plans for reopening global economies while minimizing the number of COVID-19 cases and the cost of deploying intervention plans.
To facilitate development of their proposed solutions, teams were offered free cloud and computing services from AWS.
The COVID-19 pandemic has prompted a vast spectrum of unprecedented government and community interventions. The Pandemic Response Challenge used the most advanced AI technology, coupled with some of the most creative minds in the fields of data science, computer programming, machine learning, and more, to jumpstart new strategies for effectively reopening societies and restarting economies safely for everyone – as well as test scenarios that might be applied going forward.
Moving forward, XPRIZE and Cognizant, along with International Telecommunication Union (ITU), are expanding these efforts beyond the scope of this competition to one of a public platform and ecosystem that encourages the convening of AI and data while enabling the contributions of experts and thought leaders of the global community of public health. Details of the public platform will be announced soon. Those interested in joining and contributing to these efforts are encouraged to contact XPRIZE at pandemicresponse@xprize.org .
Learn more by watching this film explaining the Pandemic Response Challenge .
About XPRIZE
XPRIZE, a 501(c)(3) nonprofit organization, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100M XPRIZE Carbon Removal, $20 Million NRG COSIA Carbon XPRIZE, $15M XPRIZE Feed the Next Billion, $10 Million XPRIZE Rainforest, $10 Million ANA Avatar XPRIZE, $6 Million XPRIZE Rapid COVID Testing, $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling, and $500K Pandemic Response Challenge. For more information, visit xprize.org.
About COGNIZANT
Cognizant (Nasdaq-100: CTSH) is one of the world's leading professional services companies, transforming clients' business, operating and technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative and efficient businesses. Headquartered in the U.S., Cognizant is ranked 194 on the Fortune 500 and is consistently listed among the most admired companies in the world. Learn how Cognizant helps clients lead with digital at www.cognizant.com or follow us @Cognizant.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005419/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
